NEUROONE MEDICAL TECHNOLOGIES Corp
For the period ended Sep 30, 2025. Filed Dec 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Dec 17, 2025
NMTC$0.89+0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| Years ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities | ||
| Net loss | $(3,605,374) | $(12,318,110) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Amortization and depreciation | 261,679 | 246,791 |
| Amortization of deferred issuance costs | 192,647 | 101,329 |
| Stock-based compensation | 1,264,608 | 1,344,476 |
| Fair value change in warrant liability | (784,670) | 327,092 |
| Debt and equity facility costs reclassified to financing activities | 141,416 | 127,659 |
| Non-cash lease expense | 111,613 | 113,534 |
| Valuation adjustments for excess or obsolete inventory | 10,000 | — |
| Change in assets and liabilities: | ||
| Accounts receivable | (1,088,169) | (176,636) |
| Inventory | 398,348 | (908,467) |
| Prepaid expenses | 75,089 | 47,285 |
| Accounts payable | 239,983 | 66,993 |
| Accrued expenses, operating lease and other liabilities | (54,442) | 16,214 |
| Net cash used in operating activities | (2,837,272) | (11,011,840) |
| Investing activities | ||
| Purchases of property and equipment | (81,742) | (120,197) |
| Net cash used in investing activities | (81,742) | (120,197) |
| Financing activities | ||
| Proceeds from issuance of common stock in connection with private placement | — | 836,777 |
| Proceeds from issuance of warrants in connection with private placement | — | 1,813,223 |
| Proceeds from issuance of common stock attributed to non-private placement equity offerings | 9,614,037 | 5,033,906 |
| Issuance costs attributed to common stock and warrants issued in private placement | (185,903) | (1,320) |
| Issuance costs related to non-private placement equity offerings | (1,045,971) | (236,597) |
| Deferred issuance costs in connection with at-the-market offering program | — | (20,000) |
| Deferred issuance costs in connection with debt facility | (297,942) | (75,000) |
| Exercise of warrants | 69,750 | — |
| Share repurchases for the payment of employee taxes | (124,617) | (81,403) |
| Net cash provided by financing activities | 8,029,354 | 7,269,586 |
| Net increase (decrease) in cash and cash equivalents | 5,110,340 | (3,862,451) |
| Cash and cash equivalents at beginning of year | 1,460,042 | 5,322,493 |
| Cash and cash equivalents at end of year | $6,570,382 | $1,460,042 |
| Supplemental non-cash financing and investing transactions: | ||
| Modification of right-of-use asset and associated lease liability | $111,898 | $199,385 |
| Non-cash warrants issued in connection with debt facility | $— | $53,124 |
| Unpaid issuance costs in connection with private placement | $— | $185,903 |
| Unpaid deferred issuance costs | $22,920 | $95,837 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.